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Abstract
Background:  Agents belonging to diverse chemical classes are used clinically as general
anesthetics. The molecular targets mediating their actions are however still only poorly defined.
Both chemical diversity and substantial differences in the clinical actions of general anesthetics
suggest that general anesthetic agents may have distinct pharmacological targets. It was
demonstrated previously that the immobilizing action of etomidate and propofol is completely, and
the immobilizing action of isoflurane partly mediated, by β3-containing GABAA receptors. This was
determined by using the β3(N265M) mice, which carry a point mutation known to decrease the
actions of general anesthetics at recombinant GABAA receptors. In this communication, we
analyzed the contribution of β3-containing GABAA receptors to the pharmacological actions of
isoflurane, etomidate and propofol by means of β3(N265M) mice.
Results: Isoflurane decreased core body temperature and heart rate to a smaller degree in
β3(N265M) mice than in wild type mice, indicating a minor but significant role of β3-containing
GABAA receptors in these actions. Prolonged time intervals in the ECG and increased heart rate
variability were indistinguishable between genotypes, suggesting no involvement of β3-containing
GABAA receptors. The anterograde amnesic action of propofol was indistinguishable in β3(N265M)
and wild type mice, suggesting that it is independent of β3-containing GABAA receptors. The
increase of heart rate variability and prolongation of ECG intervals by etomidate and propofol were
also less pronounced in β3(N265M) mice than in wild type mice, pointing to a limited involvement
of β3-containing GABAA receptors in these actions. The lack of etomidate- and propofol-induced
immobilization in β3(N265M) mice was also observed in congenic 129X1/SvJ and C57BL/6J
backgrounds, indicating that this phenotype is stable across different backgrounds.
Conclusion: Our results provide evidence for a defined role of β3-containing GABAA receptors
in mediating some, but not all, of the actions of general anesthetics, and confirm the multisite model
of general anesthetic action. This pharmacological separation of anesthetic endpoints also suggests
that subtype-selective substances with an improved side-effect profile may be developed.
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Background
The introduction of general anesthetics into medical prac-
tice 160 years ago has revolutionized surgical practice,
however, the mechanisms of action of this class of drugs
are still only poorly understood. Although general anes-
thetics have been shown to modulate the activity of a
number of proteins, e.g. ligand-gated ion channels [1] and
two-pore domain potassium channels [2]in vitro, the iden-
tification of targets mediating specific actions of general
anesthetics in vivo has only just begun.
GABAA receptors are pentameric ligand-gated ion chan-
nels, with the majority of them containing two α, two β
and one γ subunit [3]. Mutagenesis studies have identified
amino acid residues in GABAA receptor β subunits (e.g.
N265 in the β3 subunit) to be crucial for the actions of the
general anesthetics propofol and etomidate in vitro [4-8].
It has been shown that β3(N265M) mice are insensitive to
the immobilizing and respiratory depressant action of
etomidate and propofol and have a reduced sensitivity for
the hypnotic action of these drugs [9,10], suggesting that
β3-containing GABAA  receptors mediate these actions,
while etomidate retains its sedative (motor depressant)
action at subanesthetic doses. In line with these findings,
β2(N265S) mice are still sensitive to the immobilizing
and hypnotic actions of etomidate, but lack the sedative
response to low doses of etomidate [11].
Inhalation anesthetics like isoflurane show a wider range
of targets in vitro, including the GABAA receptor, glycine
receptor, 5-HT3 receptor, kainate receptor, nicotinic ace-
tylcholine receptor, AMPA receptor, and NMDA receptor
[1]. It was recently shown that the inhalational anesthetics
isoflurane, enflurane and halothane exert their immobi-
lizing action only partly via β3-containing GABAA recep-
tors [9,12-14], suggesting that other targets of these
volatile anesthetics mediate most of their immobilizing
action. The extinction of the conditioned fear response by
isoflurane, which is related to the amnestic action of iso-
flurane, on the other hand, has been suggested to be
mediated by cortical α1-containing GABAA receptors [15],
which are frequently associated with β2 subunits [16].
In this study, we assessed the effects of isoflurane on heart
rate, core body temperature and the ECG, the anterograde
amnesic action of propofol, and the effects of propofol
and etomidate on the ECG. We further assessed the
immobilizing and hypnotic action of etomidate and pro-
pofol in mice carrying the β3(N265M) mutation on con-
genic C57BL/6J and 129X1/SvJ backgrounds to confirm
the phenotype of the β3(N265M) mutation on two addi-
tional genetic backgrounds.
Results
The heart rate depressant effect of isoflurane is present 
but reduced in β3(N265M) mice
It has previously been shown that the immobilizing
action of isoflurane is mediated only in part by β3-con-
taining GABAA receptors [12,13]. We now investigated
whether the heart rate depressant action of isoflurane is
dependent on β3-containing GABAA receptors. We chose a
concentration of 1.2% isoflurane, which represents
approximately 0.7 "MAC" in wild type mice and 0.6
"MAC" in β3(N265M) mice with respect to the loss of the
hindlimb withdrawal reflex [12]. After application of
1.2% isoflurane for 40 min, the heart rate of wild type
mice decreased from a baseline value of 613 ± 18 bpm to
408 ± 27 bpm after 35 min of isoflurane application (-
34%, p < 0.001), whereas in β3(N265M) mice it
decreased from a baseline value of 585 ± 13 to 466 ± 9
bpm (-21%) (p < 0.01) (Fig. 1). The time course of heart
rate decrease is similar in wild type and β3(N265M) mice.
The decrease of the heart rate after isoflurane is signifi-
cantly smaller in β3(N265M) mice compared to wild type
mice under these experimental conditions (p < 0.001),
however, the difference is rather small and thus the heart
rate depressant action of isoflurane is largely mediated by
targets other than β3-containing GABAA  receptors.
Alphaxalone, whose action is not affected by the point
mutation [7], and which was used as a negative control,
displayed no genotype difference with respect to heart rate
depression [10], indicating that the heart rate depressant
action as such is not affected by the point mutation.
The hypothermic effect of isoflurane is present but 
reduced in β3(N265M) mice
Isoflurane decreases the core body temperature (CBT).
When mice are placed in a chamber with 1.2% isoflurane
(for 40 minutes), the CBT starts to decrease within 5 min-
utes. The CBT decreased from 36.4 ± 0.4°C and 36.1 ±
0.1°C to 30.9 ± 0.4°C (p < 0.001) and 31.6 ± 0.2°C (p <
0.001) (-16% and -12%) after 40 min of isoflurane appli-
cation in wild type and mutant mice, respectively (p <
0.05 between genotypes) (Fig. 2). The time course of
hypothermia is similar in wild type and β3(N265M) mice.
Immediately after the mouse is taken out of the isoflurane
chamber, the CBT increases again. The decrease of CBT in
the presence of isoflurane is pronounced in both geno-
types although slightly but significantly smaller in
β3(N265M) mice, indicating a minor role for the β3-con-
taining GABAA receptors in this drug action. The hypo-
thermic response to alphaxalone was not different
between β3(N265M) and wild type mice, indicating that
β3(N265M) mice respond properly to a hypothermic
challenge.BMC Pharmacology 2007, 7:2 http://www.biomedcentral.com/1471-2210/7/2
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Effects of isoflurane on ECG parameters
General anesthetics are known to alter ECG parameters in
humans. In mice, ECG changes have only been recorded
for ketamine. We determined the effects of isoflurane on
the ECG in wild type and β3(N265M) mice (Fig. 3, Table
1). In wild type mice, isoflurane increased heart rate vari-
ability, the PQ, QT, and QRS intervals. There was no gen-
otype difference in these parameters, suggesting no role of
β3-containing GABAA receptors in the effects of isoflurane
on these ECG parameters. There were also no genotype
Isoflurane-induced hypothermia Figure 2
Isoflurane-induced hypothermia. A. After application of isoflurane core body temperature (CBT) decreases in both wild-
type and β3(N265M) mice. B. Maximum CBT change after application of isoflurane compared to 1 hour baseline before appli-
cation. For comparison, values for alphaxalone are displayed as well [10]. Isoflurane: n = 7, alphaxalone i.v.: wt n = 6, 
β3(N265M) n = 6. * p < 0.05, ** p < 0.01.
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Isoflurane-induced heart rate depression Figure 1
Isoflurane-induced heart rate depression. A. After application of isoflurane heart rate (HR) decreases in both wild-type 
and β3(N265M) mice. B. Maximum HR change after application of isoflurane compared to 1 hour baseline before application. 
For comparison, values for alphaxalone, a neurosteroid whose action at the GABAA receptor is not influenced by the 
β3(N265M) point mutation, are displayed as well [10]. Isoflurane: n = 7, alphaxalone i.v.: wt n = 6, β3(N265M) n = 6. * p < 0.05, 
** p < 0.01, *** p < 0.001.
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differences after alphaxalone, indicating an unaltered
responsiveness of β3(N265M) mice to changes in the
ECG.
β3(N265M) mice on different genetic backgrounds show 
similar response to propofol and etomidate
In view of extensive literature on the influence of genetic
background in genetically modified mice, we checked
whether the response of β3(N265M) mice to general anes-
thetics is influenced by this. All experiments done in these
mice published so far [9,10] and all experiments pre-
sented so far in this communication were done with mice
harbouring the β3(N265M) point mutation on a mixed
background of 129X1/Sv × 129/SvJ. To test whether the
genetic background influences the response to etomidate-
and propofol-induced loss of righting reflex (LORR) and
loss of hindlimb withdrawal reflex (LHWR), these mice
were backcrossed 9 and 10 times, respectively, either to
C57/BL/6J or 129X1/SvJ wild type mice, to obtain the
mutation on a congenic background. These mice were
tested with etomidate (10 mg/kg i.v.) and propofol (30
mg/kg i.v.) (Fig. 4). After injection of etomidate LORR was
30 ± 6 min and 18 ± 4 min, in the C57BL/6J wild type and
129X1/SvJ wild type mice, respectively. The duration of
LHWR was 7.3 ± 0.9 min and 9.1 ± 1.3 min in C57BL/6J
and 129X1/SvJ wild type mice, respectively. Similar to
what was previously observed in the mixed background
129/Sv × 129/SvJ β3(N265M) mice [9], also in
β3(N265M) mice on the C57BL/6J and 129X1/SvJ back-
grounds, 10 mg/kg etomidate lead to a significantly
decreased LORR (14 ± 2 min, 6 ± 1 min, respectively, p <
0.05, versus wild type) and to an abolished LHWR (0 min
on both backgrounds, p < 0.001 versus the corresponding
wild type). Thus, we have observed the same phenotype in
three different backgrounds, suggesting that it is robust
across different genetic backgrounds.
Propofol induces anterograde amnesia in β3(N265M) mice
General anesthetics are known to induce anterograde
amnesia. We tested whether propofol-induced antero-
grade amnesia is mediated by β3-containing GABAA recep-
tors. Increasing doses of propofol (25, 50, 75 and 100 mg/
kg i.p.) were employed (Fig. 5). The increasing imprint
latency on the training day at the two highest doses of 75
and 100 mg/kg propofol might indicate that in both gen-
otypes mice are slightly sedated at these doses. Most
importantly, propofol decreased retrieval, i.e. the latency
to re-enter the dark compartment, to a similar degree in
wild type and β3(N265M) mice. ANOVA indicated a dif-
ference between the drug doses [F(1, 112) = 16.723, p <
0.001 overall, F(4,112) = 4.997, p < 0.001 for drug effect],
but no genotype effect [F(1,112) = 3.413, p = 0.067 for
genotype effect]. These results indicate that propofol pro-
duces anterograde amnesia in both wild-type and
β3(N265M) mice and thus by targets independent of β3-
containing GABAA receptors.
Effects of etomidate and propofol on ECG parameters
When applying etomidate and propofol via the i.v. route
and the i.p. route, we observed a strong decrease in heart
rate (see also [10]) and a prolongation of all time domain
parameters measured (RR interval, PQ interval, QRS inter-
val, and QT interval (Table 2). The heart rate variability
(HRV) increases 2.5 to 8-fold (etomidate 20 mg/kg i.p.
and etomidate 10 mg/kg i.v.) in wild type mice and 3 to
5-fold in β3(N265M) mice (propofol 30 mg/kg i.v. and
etomidate 10 mg/kg i.v.). The HRV in β3(N265M) mice
after injection of etomidate 10 mg/kg i.v. is significantly
smaller than HRV in wild type mice after etomidate 10
mg/kg i.v. (p < 0.05). No genotype differences in HRV
were noted for all other drug applications. QT, QRS and
PQ intervals are prolonged in wild type mice and
β3(N265M) mice after injection of etomidate and propo-
fol i.v. and i.p.. There is no genotype effect after injection
of any anesthetic for any interval. In summary, as men-
tioned previously for isoflurane, etomidate and propofol
induce changes in ECG parameters, which are largely
independent of β3-containing GABAA receptors.
Discussion
In this report, we investigated the contribution of β3-con-
taining GABAA  receptors to various physiological and
behavioural endpoints of the inhalational general anes-
thetic isoflurane and the intravenous general anesthetics
Table 1: Effects of isoflurane-induced anesthesia on baseline ECG parameters.
Baseline Isoflurane 1.2% Alphaxalone 15 mg/kg i.v.
wt β3(N265M) wt β3(N265M) wt β3(N265M)
RR(msec) 107 ± 3.6 108 ± 4.7 176 ± 129 128 ± 6.3 147 ± 9.7** 132 ± 2.9*
HRV(msec) 5.2 ± 0.8 5.4 ± 0.8 22 ± 2.4** 19 ± 2.7** 18.1 ± 4.1* 12.3 ± 1.6*
QT(msec) 23.5 ± 0.6 19.7 ± 0.9 26.6 ± 0.8* 24.9 ± 1* 26.6 ± 0.8 24.9 ± 1
QRS(msec) 12.2 ± 0.5 11.2 ± 0.5 14 ± 0.8* 13.0 ± 1.2 14 ± 0.8 13 ± 1.2
PQ(msec) 31.8 ± 1.3 32.2 ± 0.7 44.6 ± 1** 43.9 ± 0.7* 44.6 ± 1* 43.9 ± 0.8*
All values are mean ± SEM. RR inter-beat-interval. Group sizes: isoflurane: wt n = 7, β3(N265M) n = 7; alphaxalone i.v.: wt n = 6, β3(N265M) n = 6. 
* p < 0.05, ** p < 0.01, compared to baseline.BMC Pharmacology 2007, 7:2 http://www.biomedcentral.com/1471-2210/7/2
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propofol and etomidate. We show that the hypothermic
and cardiac depressant actions of isoflurane are to a small
but significant degree mediated by β3-containing GABAA
receptors, and that the anterograde amnestic action of
propofol is not mediated by β3-containing GABAA recep-
tors. We also found that the resistance of the β3(N265M)
mice to the immobilizing action of etomidate and propo-
fol and their partial resistance to the hypnotic action of
etomidate and propofol are present on a total of three dif-
ferent genetic backgrounds.
We studied the effects of general anesthetics in mice har-
bouring an asparagine to methionine point mutation in
position 265 of the β3 subunit of the GABAA receptor. This
point mutation renders β3-containing GABAA receptors
insensitive to the general anesthetics propofol and etomi-
date, but not to alphaxalone in a recombinant system [7].
The action of the volatile anesthetic enflurane is also
strongly reduced by the N265M point mutation in a
recombinant system [8,9]. In addition, an in vivo increase
of the EC50 values for enflurane, halothane and isoflurane
by 16%, 21%, and 24% has been reported for their immo-
bilizing action in β3(N265M) mice [9,12]. In β3(N265M)
mice the suppression of noxious-evoked movements by
etomidate and propofol, as measured by the loss of the
hindlimb withdrawal reflex was completely abolished
and the obtunding or hypnotic response, as determined
by the loss of the righting reflex, was also decreased signif-
icantly [9]. In addition, the respiratory depressant action
of propofol and etomidate was strongly reduced in the
β3(N265M) mice [10]. The β3(N265M) mice also display
Isoflurane-induced changes of ECG intervals Figure 3
Isoflurane-induced changes of ECG intervals. A, C. With application of isoflurane, QT and PQ intervals are prolonged. 
The prolongation is slightly less pronounced in β3(N265M) mice compared to wild type. B, D. Maximum change of PQ and QT 
after application of isoflurane compared to 1 hour baseline before application. For comparison, values for alphaxalone are dis-
played as well. Isoflurane: n = 7; alphaxalone i.v.: wt n = 6, β3(N265M) n = 6.
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a slightly reduced hypothermia in response to etomidate,
but not to propofol [10].
It was previously shown that isoflurane induces LORR and
LHWR largely via targets other than β3-containing GABAA
receptors, although these receptors play an appreciable
role in mediating LHWR [12,13]. In this study, we report
that core body temperature and heart rate changes in
response to isoflurane are also partly mediated by β3-con-
taining GABAA receptors, although other targets mediate a
much larger part of these responses. The decrease in the
heart rate may be secondary to the decrease in body tem-
perature and thus represent a dependent and not an inde-
pendent parameter. In humans, isoflurane decreases
blood pressure by reducing total peripheral resistance
while increasing heart rate [17]. Isoflurane depresses both
the parasympathetic and sympathetic nervous system, but
the hypotension leads to a reflex increase in sympathetic
tone, so that isoflurane depresses the parasympathetic
nervous system more than the sympathetic nervous sys-
tem, resulting in tachycardia. Increases in the plasma con-
centrations of epinephrine and norepinephrine have been
found [18], indicating activation of the sympathetic nerv-
ous system. Our observation in mice that isoflurane
decreases the heart rate might indicate a species difference
in the cardiovascular responses to this drug.
Behavioural responses to propofol and etomidate in β3(N265M) and wild type mice on pure C57/Bl6J or 129X1/SvJ back- ground Figure 4
Behavioural responses to propofol and etomidate in β3(N265M) and wild type mice on pure C57/Bl6J or 
129X1/SvJ background. A, C. Reduction in the duration of the loss of righting reflex (LORR) induced by etomidate and pro-
pofol in A) C57/Bl6J β3(N265M) and C) 129X1/SvJ β3(N265M) mice is not influenced by the genetic background. B, D. Failure 
to induce loss of hindlimb withdrawal reflex induced by propofol and etomidate in B) C57/Bl6J β3(N265M) and D) 129X1/SvJ 
β3(N265M) mice is not influenced by the genetic background. n = 10. * p < 0.05, *** p < 0.001.
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We have reported previously that the intravenous general
anesthetics etomidate and propofol reduce heart rate in
mice [10]. In humans, etomidate and propofol slightly
increase the heart rate [19]. In mice, 10 mg/kg etomidate
i.v. induces an immediate decrease of both heart rate and
core body temperature. The lowest heart rate was observed
after 15 minutes, whereas the lowest core body tempera-
ture was observed after 30 minutes. At the lowest heart
rate, the temperature drop was 4°C, whereas the maximal
temperature drop was 5°C [10]. Thus, at a point when the
heart rate already starts to recover, the core body temper-
ature is still decreasing.
The time course of heart rate and core body temperature
after 1.2% isoflurane presented in this study also shows
that the minimal heart rate is reached first, after 35 min-
Table 2: Effects of propofol- and etomidate-induced anesthesia on baseline ECG parameters.
Baseline Propofol 30 mg/kg i.v. Etomidate 10 mg/kg i.v Propofol 180 mg/kg i.p Etomidate 20 mg/kg i.p. Alphaxalone 15 mg/kg i.v.
wt β3
(N265M)
wt β3
(N265M)
wt β3
(N265M)
wt β3
(N265M)
wt β3
(N265M)
wt β3
(N265M)
RR(msec) 107 ± 3.6 108 ± 4.7 126 ± 8.5 138 ± 3.2* 205 ± 7*** 172 ± 12.8** 283 ± 32** 211 ± 29** 217 ± 7.8 154 ± 12** 138 ± 7.6** 128 ± 6.3*
HRV (msec) 5.2 ± 0.8 5.4 ± 0.8 19.7 ± 3.7 16.8 ± 2.7 40.9 ± 3.3** 27 ± 4.3*# 14.3 ± 0.4* 16 ± 1* 13.2 ± 1.2* 28 ± 5.3* 25.7 ± 6.2* 19 ± 2.7*
QT(msec) 23.5 ± 0.6 19.7 ± 0.9 28.4 ± 1.5* 24.0 ± 1.4 27.4 ± 1.2* 26.0 ± 1.5* 29.8 ± 0.9*** 26.8 ± 1.6 27.6 ± 0.9** 32.8 ± 3.7* 26.5 ± 1* 26.5 ± 1.3
QRS (msec) 12.2 ± 0.5 11.2 ± 0.5 13.6 ± 0.8 12.8 ± 1.6 14.6 ± 1* 13.7 ± 1.4 15.3 ± 0.9* 13.2 ± 1 14.2 ± 0.7** 14.6 ± 1.6 13.8 ± 1.1 13.2 ± 1
PQ(msec) 31.8 ± 1.3 32.2 ± 0.7 35.9 ± 2.5 36.4 ± 1.5* 40.4 ± 1.3*** 37.4 ± 1.2** 47.8 ± 1.7** 43.8 ± 2** 46.2 ± 2** 44.4 ± 2** 37.3 ± 1.4* 35.8 ± 1.2*
All values are mean ± SEM.. Group sizes: propofol i.v.: wt n = 7, β3(N265M) n = 5, etomidate i.v.: wt n = 7, β3(N265M) n = 7, alphaxalone i.v.: wt n 
= 6, β3(N265M) n = 6, propofol i.p.: wt n = 4, β3(N265M) n = 6, etomidate i.p.: wt n = 5, β3(N265M) n = 5. * p < 0.05, ** p < 0.01, *** p < 0.001 
compared to baseline, # p < 0.05 wild type compared to β3(N265M) mice. Treatment with all different vehicles alone did not lead to statistically 
significant changes of the ECG parameters recorded compared to baseline. Statistical comparison of drug values with vehicle values and of drug 
values with baseline values yields similar results.
Propofol induces anterograde amnesia in β3(N265M) mice Figure 5
Propofol induces anterograde amnesia in β3(N265M) mice. Dose-dependent effect of propofol on imprint and 
retrieval in both β3(N265M) and wild type mice. n = 15.
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utes, and the minimal temperature after 40 minutes. After
35 minutes, the temperature drop was 5.2°C, whereas the
maximal temperature drop after 40 minutes was 5.5°C.
The heart rate appears to recover before the core body
temperature has reached its lowest point, and notably, the
heart rate increased before the isoflurane application was
stopped, whereas the body temperature only increased
after the end of isoflurane application. Thus, for both the
intravenous anesthetic etomidate and the volatile anes-
thetic isoflurane, significant hypothermia develops before
the peak drug effects on heart rate are reached, and the
time courses of recovery of cardiac depression and hypo-
thermia are different.
Our current and previous studies do not address the ques-
tion whether heart rate depression and hypothermia are
dependent or independent variables, which would
require "clamping" of the core body temperature during
application of anesthetics. Both the drop in heart rate and
the drop in core body temperature both in response to
etomidate [10] and isoflurane are largely dependent on
targets other than β3-containing GABAA receptors and
only to a minor degree by β3-containing GABAA receptors.
The slightly different time course of hypothermia and
bradycardia for both etomidate and isoflurane might sug-
gest that these parameters might be at least in part inde-
pendent. Interestingly, there is no genotype difference
between  β3(N265M) mice and wild type mice the for
drop in heart rate and the drop in core body temperature
after alphaxalone/alphadolone [10], which is not affected
by the point mutation, indicating that the β3(N265M)
display a normal response to an anesthetic challenge.
Since mice are small animals, their ratio of body surface to
body mass is relatively high and thus hypothermia is
expected to be more pronounced than in humans with
comparable challenges. It should be noted that the clear
species differences especially with respect to changes in
heart rate suggest that extrapolation of mouse data to
humans should be done with great caution.
General anesthetic agents also alter electrocardiographic
(ECG) intervals and decrease heart rate variability in
humans as was shown for induction with the barbiturate
thiopentone and subsequent inhalation of isoflurane-
nitrous oxide [20]. Here, we report that heart rate variabil-
ity (HRV) is increased by general anesthetics in mice. HRV
is considered to be an indicator of cardiac vagal control,
and drugs increasing HRV have been shown to reduce
mortality and sudden death in severe heart failure in clin-
ical trials [21]. Our finding might indicate that general
anesthetics reduces sympathetic tone in mice [22] which
results in prolongation of time domain intervals such as
QT, QRS and PQ and in an increase in HRV. We showed
an increase of HRV after all anesthetics tested, but most
pronounced in wild type mice after application of etomi-
date i.v.. The increase in HRV after etomidate is slightly
but significantly reduced in β3(N265M) compared to
wild type mice. Prolongation of QT, QRS and PQ intervals
is similar in β3(N265M) and wild type mice. To our
knowledge, no central mechanisms of HRV regulation
have been investigated in mice. In the periphery, β-adren-
ergic receptors expressed in cardiac tissue are thought to
regulate HRV [23]. β1 and β2-ARs play differential roles in
the modulation of HRV, each receptor subtype regulating
different frequency components of HRV [23]. Etomidate
is also known to have agonist activity at α2 adrenergic
receptors [24], and it is conceivable that some of its effects
on heart rate variability are mediated by these receptors.
β3-containing GABAA receptors might play a role in the
central regulation of HRV. In general, it should be kept in
mind that the ECG in the mouse, as performed in this
study, is recorded from only two electrodes and informa-
tion is thus much more limited than information
obtained from ECG in humans.
Based on differential sensitivities to propofol of inbred
long sleep (ILS) and inbred short sleep (ISS) mice, it has
been postulated that a gene responsible for the LORR
induced by propofol, termed Lorp1, would be located in a
99% confidence interval from 71.4–89.7 Mb on mouse
chromosome 7 [25], and in addition, an etomidate-sensi-
tivity quantitative trait locus (QTL) has also been identi-
fied in this chromosome region [26,27]. So far, the
identity of the Lorp1 gene is unknown. Interestingly, the
Gabrb3 gene encoding the β3 subunit of the GABAA recep-
tor is also located on mouse chromosome 7, between 57.4
and 57.7 Mb. To ascertain that the phenotype previously
described in 129/Sv × 129/SvJ mice, i.e. partial loss of
LORR and complete loss of LHWR in response to etomi-
date and propofol in β3(N265M) mice [9] is really due to
the point mutation in the GABAA receptor β3 subunit, the
mutant mice were bred for 10 and 9 generations, respec-
tively, onto the 129X1/SvJ and C57BL/6J backgrounds, to
yield congenic mice. In all backgrounds examined, we
observed the same phenotype, demonstrating that this
phenotype is very robust across different backgrounds,
and thus that the observed phenotype is really associated
with the N265M point mutation in the Gabrb3 gene. Thus,
our analysis shows that Gabrb3 and Lorp1 are separate
genes.
We further tested β3(N265M) mice on the congenic
129X1/SvJ background in the passive avoidance para-
digm, to examine whether the anterograde amnesic action
of propofol would be mediated by β3-containing GABAA
receptors. Our results suggest that this anesthetic end-
point is independent of β3-containing GABAA receptors.
This result is consistent with previous findings that both
the anterograde amnesic action of diazepam [28] (studied
using the same paradigm) as well as the anterogradeBMC Pharmacology 2007, 7:2 http://www.biomedcentral.com/1471-2210/7/2
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amnesic action of isoflurane (determined as an extinction
of conditioned fear response) [15] are mediated by α1-
containing GABAA receptors. Since α1β2γ2 is the most
abundant GABAA receptor subtype [29], it is tempting to
speculate, and consistent with all data currently available,
that this receptor subtype mediates the anterograde amne-
sic actions not only of sedative-hypnotic agents like
diazepam (Rudolph et al., 1999), but also of general anes-
thetic agents. However, in α5-/- mice, long term potentia-
tion (LTP) in CA1 is reduced by etomidate in wild type but
not in α5-/- mice [30]. Furthermore, learning in the Morris
water maze and in fear conditioning is impaired by etomi-
date in wild type mice, but not in α5-/- mice [30]. These
data indicate a role for α5-containing GABAA receptors in
drug-induced amnesia, in addition to its involvement in
certain hippocampus-dependent forms of associative
learning like trace fear conditioning [30,31].
Our current knowledge on the role of β3-containing
GABAA receptors in the action of the general anesthetics
etomidate, propofol and isoflurane is summarized in
Table 3. The genetic dissection of the pharmacological
spectrum of general anesthetics is of interest for the design
of novel general anesthetic compounds, in which the var-
ious desired and undesired effects can be separated.
Conclusion
We show that β3-containing GABAA receptors mediate a
small, but significant, part of isoflurane-induced heart rate
depression and hypothermia, which is in line with the
small but significant contribution of β3-containing
GABAA receptors to isoflurane-induced immobility and
hypnosis reported previously. We also found that isoflu-
rane-induced ECG changes are not mediated by β3-con-
taining GABAA  receptors. These data indicate that
isoflurane exerts its effects via many targets, β3-containing
GABAA receptors being one of them. Furthermore, we
found a dissociation between the immobilizing and
anterograde amnestic action of propofol. Whereas as pre-
viously shown the immobilizing action of etomidate is
mediated by β3-containing GABAA receptors, the antero-
grade amnesic action is independent of this receptor sub-
type. Prolongation of ECG intervals induced by etomidate
and propofol was not mediated by β3-containing GABAA
receptors. By demonstrating that etomidate- and propo-
fol-induced immobilization is mediated exclusively and
hypnosis is mediated partly by β3-containing GABAA
receptors in two congenic backgrounds, we show that this
phenotype is robust across three backgrounds and that the
Gabrb3 locus is different from the Lorp1 locus.
Methods
Animals
Generation, characterization and breeding of β3(N265M)
mice has been described previously [9]. Mice used for
telemetry were 3 months old at the time of surgery, 4
months old at the beginning of the experiments and 10
months at the end of the telemetry experiments. Mice
used in the passive avoidance paradigm were 6 to 8 weeks
old, and mice used for reflex tests were 4 to 7 months old.
Telemetry experiments were performed on 129/Sv ×
129X1/SvJ (12.5%/87.5%) mice, anterograde amnesia
was performed on a congenic 129X1/SvJ background (10
backcrosses with 129X1/SvJ), and loss of righting reflex
and loss of hindlimb withdrawal reflex were performed
on a congenic 129X1/SvJ background (10 backcrosses
with 129X1/SvJ) and a congenic C57BL/6J background (9
generations of backcrosses with C57BL/6J mice). All ani-
mal experiments have been approved by the cantonal vet-
erinary office in Zurich.
Surgery
16 female mice (8 β3(N265M) mice and 8 wild type con-
trols) were implanted under isoflurane anaesthesia (3–
5% in oxygen) with intraperitoneal radiotelemetry trans-
mitters for measuring core body temperature, ECG and
activity (model No. ETA-F20, Data Sciences International
(DSI), St. Paul, MN). The transmitter body was implanted
under sterile conditions in the abdominal cavity and the
sensing leads were positioned as described previously
[32]. Mice received postoperative antibiotics (20 mg/kg
sulfadoxin, 5 mg/kg trimethoprim, Borgal 7.5%, Hoechst
Roussel vet, Provet AG, Lyssach, Switzerland) and postop-
erative pain treatment for 5 days (2.5 mg/kg flunixin s.c.,
Finadyne, BERNA Veterinärprodukte AG, Berne, Switzer-
land). Mice were allowed to recover for 4 weeks before the
first experiment. To ascertain full recovery after surgery we
measured core body temperature and heart rate over 72 h.
Experimental Conditions
Mice implanted with telemetry transmitters were singly
housed in standard laboratory conditions with a 12 h
light/dark schedule (lights on 8:00 am, lights off 8:00 pm)
and free access to food and water. Experiments were per-
formed between 9 am and 12 am. Mice used for passive
avoidance and reflex tests were group housed. The passive
avoidance experiment was performed between 9 am and
12 am, the reflex tests between 8 am and 5 pm.
Effect of Anesthetics on Core Body Temperature (CBT), 
Heart Rate (HR) and ECG Parameters (PQ, QRS, QT, 
heart rate variability(HRV))
For drug and vehicle administration experiments, a base-
line was recorded between 0 and 2 hours after lights on
and drugs were administered immediately afterwards.
Drug effects were compared to vehicle effects, which did
not differ significantly from baseline, except for isoflu-
rane, where the drug effect was compared to baseline.
Mice were treated (in this order) with 30 mg/kg propofol
i.v. (Sigma-Aldrich Chemicals, Buchs, Switzerland), 10BMC Pharmacology 2007, 7:2 http://www.biomedcentral.com/1471-2210/7/2
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mg/kg etomidate i.v. (Janssen-Cilag, Neuss, Germany), 15
mg/kg alphaxalone i.v. (Saffan®, alphaxalone/alphad-
olone 15/5 mg/kg), isoflurane 1.2% in air (Arovet, Zol-
likon, Switzerland), pentobarbital 60 mg/kg i.p.
(Nembutal, Abbott AG, Baar, Switzerland/Abbott Labora-
tories, Chicago, USA), 180 mg/kg propofol i.p., 20 mg/kg
etomidate i.p. (see also [10]). Vehicle solutions were as
follows: propofol, 14% Cremophor EL, etomidate 35%
propylene glycol, Saffan® 0.9% saline. The doses used for
the i.v. route have been previously examined for their
effects on loss of reflexes [9]. Intravenous injections were
performed in the tail vein after warming the tail in 39°C
warm water to achieve vasodilatation. The doses for the
i.p. route were determined in pre-tests. The conditions for
isoflurane application were chosen to ensure that animals
would not die of hypothermia, since animals were not
warmed up with an external heating source. For assess-
ment of the effect of isoflurane, a sealed Plexiglas chamber
was used as described previously [12]. Only one mouse at
one time was placed into the chamber to avoid overlap-
ping of the radio transmitter signals. After turning on the
transmitters with a magnet, a one hour baseline was meas-
ured with data sampling for 30 s every 3 minutes. Five
minutes before injection the sampling schedule was
switched to continuous ECG recording and body temper-
ature and heart rate were sampled every 30 s. Two hours
after the return of the righting reflex the continuous sam-
pling was switched to a data sampling for 30 s every 3
minutes and then continued for another 15 hours. Data
were acquired with the Dataquest ART 3.0 acquisition sys-
tem (DataSciences International, St. Paul, MN, USA). All
signals (CBT, HR and ECG parameters) were recorded
simultaneously in the same experiment. CBT and HR were
calculated by the acquisition software (Dataquest A.R.T.
3.01, Data Sciences International). The ECG signal was
further processed to derive time domain parameters (PQ,
QRS, QT) with the Physiostat™ ECG Analysis 4.00
(DataSciences International) software.
Amnestic effect of propofol in a passive avoidance task
The amnestic effect of propofol was tested in a single-trial
passive avoidance task. Propofol was injected 20 min
before training at 0, 25, 50, 75 and 100 mg/kg i.p. After
injection, mice were put back in their home cage and after
20 min, when the drug effect was fully developed, they
were placed in a lit chamber (860 lux light intensity). Mice
were allowed to explore the chamber for 30 sec, then a
door was opened to a dark chamber and latency of the
mouse to enter the dark chamber was measured
(imprint). The door was closed and 10 sec later two foot
shocks with 0.5 mA strength at an interval of 3 sec were
applied. Retention was tested 24 h after training as latency
to re-enter the dark chamber (retrieval). The experimenter
was blinded to genotype and substance.
Statistical Analysis
Results are expressed as mean ± SEM. For analysis of
telemetry data statistical differences were assessed by
using the paired Student's t-test for testing whether the
effect of anesthetic is significant compared to the vehicle,
and the unpaired Student's t-test for determining poten-
tial genotype differences between wild type and mutant
mice. The minimum CBT or HR after injection of anes-
thetic and the mean of vehicle values over a time period
of two hours after injection were determined and com-
pared to the mean of one hour baseline before injection.
For analysis of passive avoidance data, repeated measures
ANOVA followed by a post hoc Bonferroni test was used.
For analysis of reflex data, the unpaired Student's t-test
was used.
List of abbreviations
GABA γ-aminobutyric acid
GABAA receptor GABA type A receptor
HR heart rate
Table 3: Proposed roles of β3-containing GABAA receptors in the actions of the general anesthetics etomidate, propofol and 
isoflurane
Etomidate Propofol Isoflurane
Immobility +++9 +++9 +12
Hypnosis ++9,11 ++9 +12
Respiratory depression +++10 +++10 n.d.
Sedation ---11 n.d. n.d.
Anterograde amnesia n.d. --- n.d.
Hypothermia +10 ---10 +
Heart rate depression +10 ---10 +
ECG changes --- --- ---
+++ designates complete mediation of this action by β3-containing GABAA receptors. ++ designates partial mediation (approximately 50%), + 
designates a small but significant contribution of β3-containing GABAA receptors. --- designates no mediation at all or a very minor contribution 
through β3-containing GABAA receptors. n.d. not determined. Data which were taken from the literature are marked with superscripts, which 
refer to this paper's reference list. Heart rate depression might be secondary to hypothermia.BMC Pharmacology 2007, 7:2 http://www.biomedcentral.com/1471-2210/7/2
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CBT core body temperature
ECG electrocardiogram
LTP long term potentiation
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